Shamburg News · 8-K filed Oct 19, 2026, 8:05 AM EDT

Silence Therapeutics to Be Acquired by Merck KGaA, Darmstadt, Germany for $20.00 per ADS in Cash

SLNCF · Silence Therapeutics plc

  • Material agreement
  • Acquisition
  • Reg FD disclosure
  • Materiality: high

On October 18, 2026, Silence Therapeutics plc entered into a Transaction Agreement with Merck KGaA, Darmstadt, Germany under which Merck KGaA will acquire all ordinary shares via a U.K. scheme of arrangement for $20.00 in cash per American Depositary Share ($6.6667 per ordinary share). The filing states the Company's board recommended the transaction and securityholders holding approximately 14% of voting power have signed voting and support agreements. Completion is subject to shareholder approvals, regulatory clearances and Court sanction, with an End Date of April 30, 2027 and a $13 million termination fee payable in specified circumstances.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 1.01, 7.01, 9.01, accession 0001193125-26-424695.

Written from the filing by Shamburg Markets. Figures are as reported by the company.